Lorena Flor da Rosa Franchi Santos1, Neide Tomimura Costa2, Michael Maes3, Andréa Name Colado Simão4, Isaias Dichi5. 1. Laboratory of Research in Applied Immunology, University of Londrina, Londrina, PR, Brazil. 2. Department of Rheumatology, University of Londrina, Londrina, PR, Brazil. 3. IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, VIC, Australia. 4. Department of Pathology and Clinical Analysis and Toxicology, Laboratory of Research in Applied Immunology, University of Londrina, Rua Robert Koch, n 60., Londrina, PR, Brazil. deianame@yahoo.com.br. 5. Department of Internal Medicine and Laboratory of Research in Applied Immunology, University of Londrina, Londrina, PR, CEP 86038-440, Brazil.
Abstract
BACKGROUND: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are autoimmune diseases characterized by changes in cell adhesion molecules (CAMs). OBJECTIVE: To review the influence of the main drugs used in the treatment of SLE and RA on CAM levels. METHODS: A bibliographic search was performed using electronic databases. The research included human studies, in vivo or in vitro, with an experimental or observational design, and with no limit of publication date or number of subjects. Animal studies and non-standard treatments were not considered. RESULTS: We included 21 studies, 3 on SLE and 18 on RA with monotherapy or combined trials. The most used drugs were cyclophosphamide (CY, in 2 studies) and methylprednisolone pulse (pMP, n = 2) in SLE; and methotrexate (MTX, n = 9) and infliximab (IFX, n = 4) in RA. In addition, the most frequently examined CAMs to predict response to treatment were vascular cell adhesion molecule-1 (VCAM-1, n = 2) in SLE, and intercellular adhesion molecule-1 (ICAM-1, n = 12), VCAM-1 (n = 12), and E-selectin (n = 14) in RA. After treatment, CAM levels were decreased in SLE and RA patients with active disease. CONCLUSIONS: It is concluded that the CAM biomarkers may reflect disease activity and the response to treatment in SLE and RA patients.
BACKGROUND:Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are autoimmune diseases characterized by changes in cell adhesion molecules (CAMs). OBJECTIVE: To review the influence of the main drugs used in the treatment of SLE and RA on CAM levels. METHODS: A bibliographic search was performed using electronic databases. The research included human studies, in vivo or in vitro, with an experimental or observational design, and with no limit of publication date or number of subjects. Animal studies and non-standard treatments were not considered. RESULTS: We included 21 studies, 3 on SLE and 18 on RA with monotherapy or combined trials. The most used drugs were cyclophosphamide (CY, in 2 studies) and methylprednisolone pulse (pMP, n = 2) in SLE; and methotrexate (MTX, n = 9) and infliximab (IFX, n = 4) in RA. In addition, the most frequently examined CAMs to predict response to treatment were vascular cell adhesion molecule-1 (VCAM-1, n = 2) in SLE, and intercellular adhesion molecule-1 (ICAM-1, n = 12), VCAM-1 (n = 12), and E-selectin (n = 14) in RA. After treatment, CAM levels were decreased in SLE and RApatients with active disease. CONCLUSIONS: It is concluded that the CAM biomarkers may reflect disease activity and the response to treatment in SLE and RApatients.
Authors: D T Boumpas; H A Austin; E M Vaughn; J H Klippel; A D Steinberg; C H Yarboro; J E Balow Journal: Lancet Date: 1992-09-26 Impact factor: 79.321
Authors: M P Bombara; D L Webb; P Conrad; C W Marlor; T Sarr; G E Ranges; T M Aune; J M Greve; M L Blue Journal: J Leukoc Biol Date: 1993-11 Impact factor: 4.962
Authors: M Bonelli; E Ferner; L Göschl; S Blüml; A Hladik; T Karonitsch; H P Kiener; R Byrne; B Niederreiter; C W Steiner; E Rath; M Bergmann; J S Smolen; C Scheinecker Journal: Arthritis Rheum Date: 2013-03
Authors: Paul F Bradfield; Nicole Amft; Elizabeth Vernon-Wilson; Andrew E Exley; Greg Parsonage; G Ed Rainger; Gerard B Nash; Andrew M C Thomas; David L Simmons; Mike Salmon; Christopher D Buckley Journal: Arthritis Rheum Date: 2003-09